US Patent

US11185541 — Methods for treating antipsychotic-induced weight gain

Method of Use · Assigned to Alkermes Pharma Ireland Ltd · Expires 2031-08-23 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for reducing weight gain associated with atypical antipsychotic medications, such as Zyprexa.

USPTO Abstract

The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3140 — Zyprexa
U-3140 — Zyprexa
U-3140 — Zyprexa
U-3140 — Zyprexa

Patent Metadata

Patent number
US11185541
Jurisdiction
US
Classification
Method of Use
Expires
2031-08-23
Drug substance claim
No
Drug product claim
No
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.